110 J. Bazoma et al.: Radioprotection 2026, 61( 2), 105 – 112
Table 6. Median and 75 th percentile( in mGy) of the distribution of SSDE per examination type. Female Male Overall
Examination |
Q2 |
Q3 |
Q2 |
Q3 |
Q2 |
Q3 |
Chest |
5.0 |
6.8 |
4.2 |
4.8 |
4.3 |
6.2 |
AP |
5.2 |
6.2 |
4.3 |
4.5 |
4.5 |
5.4 |
CAP |
5.2 |
6.7 |
4.3 |
4.7 |
4.7 |
5.8 |
Q2 = Second quartile = Median; Q3 = Third quartile = 75 th percentile.
Table 7. Mean and median effective dose( mSv) for head, chest, AP and CAP scans. Patient Female Male Overall
Examination |
Mean ± 1s |
Median |
Mean ± 1s |
Median |
Mean ± 1s |
Median |
Head |
1.6 ± 0.2 |
1.6 |
1.2 ± 0.2 |
1.3 |
1.4 ± 0.2 |
1.3 |
Chest |
2.7 ± 2.2 |
2.4 |
1.8 ± 0.5 |
1.6 |
2.3 ± 1.7 |
1.7 |
AP |
3.2 ± 1.8 |
2.8 |
2.2 ± 0.9 |
2.0 |
2.8 ± 1.5 |
2.2 |
CAP |
3.3 ± 1.9 |
2.7 |
2.1 ± 0.3 |
2.2 |
2.9 ± 1.7 |
2.4 |
s = Standard deviation. Table 8. Comparison of CTDI vol and DLP median values with DRLs reported in other studies.
This study( Median values)
DLP( mGy cm) Other Studies( DRL *)
Examination |
Congo |
Congo( Dallou, 2024) |
Nigeria( Kabeer, 2024) |
Lebanon( Hakme, 2023) |
Morocco( El Fahssi, 2024) |
Head |
1172.2 |
637.3 |
1044 |
1104 |
1405.8 |
Chest |
158.3 |
708.4 |
372 |
483 |
417.7 |
AP |
163.2 |
740.1 |
646 |
442 |
444.5 |
CAP |
203.6 |
866.3 |
– |
611 |
571.3 |
CTDI vol( mGy)
This study( Median values)
Other Studies( DRL *)
Examination |
Congo |
Congo( Dallou, 2024) |
Nigeria( Kabeer, 2024) |
Lebanon( Hakme, 2023) |
Morocco( El Fahssi, 2024 |
Head |
57 |
44.3 |
48.2 |
65 |
64.5 |
Chest |
2.7 |
22.0 |
9.4 |
15 |
11.1 |
AP |
3.2 |
19.8 |
8.0 |
9 |
8.1 |
CAP |
3.2 |
19.8 |
– |
13 |
8.5 |
Typical values determined for chest, AP, CAP scans are significantly lower than those established in these studies. Overall, the same trend is observed in Table 8 in the case of CTDI vol.
3.7 Organ and effective doses: comparison with selected studies
In the case of head scan, the brain dose( 40.9 mGy), the eye lens dose( 48.5 mGy) and the salivary gland dose( 38.4 mGy) determined in the present study are lower than those determined in Nigeria( brain dose = 75.4 mGy, eye lens dose = 107.2 mGy)( Etim Ekpo, 2018), and in the USA( brain dose = 49.3 mGy, eye lens dose = 59.9 mGy, salivary gland dose = 45.8 mGy)( Gao, 2020). The effective dose( E = 1.3 mSv) associated with head scan is lower than the value determined in Nigeria( E = 6.6 mSv)( Etim Ekpo, 2018), and in the USA( E = 2.7 mSv)( Gao, 2020), but is greater than the value determined in Iran( E = 0.7 mSv)( Khoramian, 2017).
Concerning chest scan, the lung dose( 3.5 mGy) and the breast dose( 3.3 mGy) determined in the present study are lower than those determined in Nigeria( lung dose = 18.9 mGy, breast dose = 24.4 mGy)( Etim Ekpo, 2018), in the USA( lung dose = 9.1 mGy, breast dose = 7.3 mGy)( Gao, 2020), and in Iran( lung dose = 9.3 mGy, breast dose = 4.2 mGy)( Khoramian, 2017). The effective dose( E = 1.7 mSv) associated with chest scan is lower than the value determined in Nigeria